Unlocking Personalized Medicine through Molecular Diagnostics
Personalized medicine remains an area of huge opportunities and promise for diagnostics companies, but capturing the real value will require a disruption of the current reimbursement and delivery model. To enhance your fair share of value in this huge market Genetic InsidER organizes the first commercially focused congress for Molecular Diagnostics stakeholders.
The opportunity is sizeable: +8,000 monogenic genetic diseases, as well as many cancers caused by the combination of certain mutations with any number of undefined environmental factors would be diagnosed and treated more appropriately and faster with personalized medicine. This market has made $1tn in 2014 and forecasts expect to double it for 2022 with $2.5tn, it’s time to face up the challenges.
In this congress you’ll learn about:
– Latest developments and trends in diagnostics technologies in the personalized medicine industry
– Disruptive and sustainable business models to capture value for Diagnostics
– Understanding how to increase physician awareness and demand
– Regulatory frameworks 2.0 – The keys to Market Access
– The key to American Market Access for European companies
– Demonstrate the value of diagnostic technologies to secure coverage and payment
– Clarify the uncertainty on reimbursement and managing stakeholder
Half of all pharma companies are already integrating personalized medicine in their future strategy and business models; become part of the health care disruption by enshrining its mission in the very DNA of your company to bullet proof your strategy today.
Don’t miss out the first commercially focused congress for the companion diagnostics industry! The brochure has all the information you need regarding speakers, agenda, ticket prices and many other details about the congress. Now it’s available to download, get it today here in 10 seconds: www.genetic-insider.com/diagnostics/brochure